Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | DHODH | Q02127 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.56 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246433 | 0.90 | MEN1 (0.86) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL30686767 | 0.90 | MEN1 (0.86) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL14855642 | 0.89 | KMT2A (0.79) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL414754 | 0.88 | MEN1 (0.83) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL31053873 | 0.88 | MEN1 (0.83) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL14855907 | 0.87 | DHODH (0.73) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL2029098 | 0.87 | MEN1 (1.00) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL8439303 | 0.87 | MEN1 (0.80) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL15183709 | 0.85 | KMT2A (0.77) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL14855554 | 0.85 | KMT2A (0.77) | KMT2AMEN1PKMDHODHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2011097600-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | KMT2A 1477/4885MEN1 4601/4885PKM 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.